Page last updated: 2024-09-04

glucagon and roflumilast

glucagon has been researched along with roflumilast in 1 studies

Compound Research Comparison

Studies (glucagon)	Trials (glucagon)	Recent Studies (post-2010) (glucagon)	Studies (roflumilast)	Trials (roflumilast)	Recent Studies (post-2010) (roflumilast)
26,039	1,498	3,054	566	90	425

Protein Interaction Comparison

Protein	Taxonomy	roflumilast (IC50)
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.0008
Chain B, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.0008
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)	0.0008
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)	0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.0058
cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)	0.0008
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A	Homo sapiens (human)	0.0008
cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)	0.0008
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)	0.0005
Sodium-dependent serotonin transporter	Rattus norvegicus (Norway rat)	0.0003
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)	0.0008
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.025
cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)	0.0008
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.0475
cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)	0.0008
Beta-2 adrenergic receptor	Cavia porcellus (domestic guinea pig)	0.001
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A	Homo sapiens (human)	0.0008
cAMP-specific 3',5'-cyclic phosphodiesterase 7B	Homo sapiens (human)	0.0008
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)	0.0008

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bredenbröker, D; Brose, M; Fabbri, LM; Göke, B; Rabe, KF; Teichmann, P; Wouters, EF	1

Trials

1 trial(s) available for glucagon and roflumilast

Article	Year
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:9 Topics: Adult; Aged; Aminopyridines; Area Under Curve; Benzamides; Blood Glucose; Body Weight; C-Peptide; Cyclopropanes; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glycated Hemoglobin; Glycerol; Homeostasis; Humans; Insulin; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sample Size	2012

Article

Year

Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.

The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:9

Topics: Adult; Aged; Aminopyridines; Area Under Curve; Benzamides; Blood Glucose; Body Weight; C-Peptide; Cyclopropanes; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glycated Hemoglobin; Glycerol; Homeostasis; Humans; Insulin; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sample Size

2012